Tumor response (partial response or complete response) as measured by RECIST at months 2 or 3 and 6 during study treatment, and 6 months after study completion [ Time Frame: months 2 or 3 and 6 during study treatment, and 6 months after study completion ] [ Designated as safety issue: No ]

Progression-free survival as measured by RECIST at months 2 or 3 and 6 during study treatment and every 6 months after study completion [ Time Frame: months 2 or 3 and 6 during study treatment and every 6 months after study completion ] [ Designated as safety issue: No ]

Event-free survival as measured by RECIST at months 2 or 3 and 6 during study treatment and every 6 months after study completion [ Time Frame: months 2 or 3 and 6 during study treatment and every 6 months after study completion ] [ Designated as safety issue: No ]

Overall survival beginning at the date of study entry [ Time Frame: 5 years or until death, whichever came first. ] [ Designated as safety issue: No ]

Patients undergo leukapheresis to obtain peripheral blood mononuclear cells (PBMC). The PBMC are incubated over 7 days with sargramostim (GM-CSF) and interleukin-4 to produce dendritic cells (DC). The DC are incubated over 2-3 days with the irradiated tumor cells from the autologous tumor cell line for antigen loading of the DC.

No concurrent digoxin or other medications designed to improve cardiac output

No other concurrent anticancer therapy or investigational therapy

Contacts and Locations

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study.
To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.
For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00014131